Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Capecitabine: Mechanism and Preclinical Use
2026-09-05
Capecitabine is a fluoropyrimidine prodrug that is enzymatically converted to 5-fluorouracil and studied for tumor-selective chemotherapy mechanisms. Its strongest preclinical value is as a controllable tool for apoptosis, tumor-stroma modeling, and colon cancer research, while patient-derived assembloids clarify why stromal context can alter drug response.
-
VX-661 and the Next Era of CFTR Rescue
2026-09-05
VX-661, a F508del CFTR corrector, offers more than a trafficking-rescue tool: it provides a way to interrogate how protein folding, calnexin-dependent proteostasis, variant biology, and potentiator timing shape translational cystic fibrosis research.
-
DCPS and m7G Signaling in Diabetic Foot Ulcers
2026-09-04
A 2025 study identified the m7G-related decapping scavenger enzyme DCPS as a candidate biomarker and regulator of epithelial behavior in diabetic foot ulcers. Its integrated bioinformatics, patient and mouse validation, and keratinocyte knockdown experiments connect reduced DCPS with impaired cell-cycle progression, proliferation, migration, and increased apoptosis.
-
v-Agatoxin-IVA and N-Type Calcium Channel Blockade
2026-09-04
Sidach and Mintz showed that v-agatoxin-IVA remains a selective high-affinity blocker of P-type calcium channels but can also inhibit N-type currents at higher concentrations. Their voltage-clamp analysis explains why toxin concentration, membrane potential, and cellular context are essential when distinguishing P-, Q-, and N-type channel contributions.
-
CP-673451: Selective PDGFRα/β Inhibitor Workflows
2026-09-03
CP-673451 enables focused interrogation of PDGFR-α/β signaling, PDGF-BB-driven angiogenesis, and tumor biology with less interference from several neighboring kinases. This practical guide connects phospho-signaling assays, ATRX-stratified glioma experiments, and xenograft readouts to reproducible workflow and troubleshooting decisions.
-
Abiraterone acetate in 3D Prostate Cancer Models
2026-09-02
Use Abiraterone acetate as a controlled CYP17 inhibitor probe in patient-derived prostate spheroids, where drug penetration, androgen signaling, and tumor heterogeneity can be evaluated together. The workflow below combines formulation-aware handling with orthogonal viability, PSA, immunohistochemistry, and androgen receptor readouts.
-
Hoechst 33342 for Live-Cell Nuclear Imaging
2026-09-02
Hoechst 33342 supports consistent nuclear segmentation across live-cell imaging, fixed-cell immunofluorescence, and flow cytometry workflows. This practical guide shows how to use the 1 mg/mL reagent to strengthen dermal fibroblast senescence assays without treating nuclear fluorescence as a standalone biological endpoint.
-
ATP Workflows for OGDH Metabolism Research
2026-09-02
Use ATP to connect mitochondrial enzyme activity, proteostasis, and purinergic signaling in experimentally controlled workflows. This guide translates the TCAIM–OGDH discovery into practical ATP titrations, native-protein assays, extracellular stimulation studies, and troubleshooting decisions.
-
Mitochondrial Calcium Signaling Represses Ferroptosis
2026-09-01
The reference study identifies mitochondrial calcium uptake through MCU as a regulator of ferroptosis resistance, linking mitochondrial acetyl-CoA production to GPX4 acetylation and activity. Genetic and structural evidence further connects this pathway to tumor growth, providing a mechanistic framework for studying how mitochondrial metabolism shapes lipid-peroxide defense.
-
Sildenafil Citrate: Vascular Signaling Workflows
2026-08-31
Build reproducible PDE5 experiments that connect cGMP accumulation with vascular smooth muscle relaxation, ERK signaling, and functional tissue responses. This guide also shows how to extend conventional cell assays toward proteoform-aware native membrane studies while avoiding common solubility, vehicle, and off-target interpretation errors.
-
Lipid Peroxidation (MDA) Assay Kit Workflow
2026-08-31
Build a reliable malondialdehyde workflow for tissue, cell, plasma, serum, and urine samples using matched colorimetric and fluorescence readouts. This guide connects MDA quantification to ferroptosis and sepsis-associated kidney injury while emphasizing matrix control, calibration, and troubleshooting.
-
Balsalazide disodium in IBD research
2026-08-30
Balsalazide disodium enables researchers to connect colonic bacterial activation with localized 5-aminosalicylic acid biology. This guide turns that mechanism into practical workflows for inflammation research, immunology assays, and inflammatory bowel disease models, with concentration planning and troubleshooting guidance.
-
Vemurafenib (PLX4032) Melanoma Workflow
2026-08-29
Build more informative BRAF-mutant melanoma experiments with Vemurafenib (PLX4032), from concentration-response assays to time-resolved resistance profiling. This workflow pairs pathway pharmacology with ARID1A-aware multi-omics design to distinguish on-target response, adaptive signaling, and stable resistance.
-
AAL-993: VEGF Receptor Inhibitor to Translation
2026-08-28
A mechanistic and translational framework for using AAL-993 to connect VEGF receptor blockade, angiogenesis biology, melanoma models, and network-informed glioma research.
-
CP-673451: From PDGFR Potency to Assay Insight
2026-08-28
CP-673451 is a selective PDGFRα/β inhibitor for dissecting receptor phosphorylation, angiogenesis, and tumor biology. This article presents an assay-centered framework that connects its pharmacology with ATRX-aware glioma research while defining practical controls and translational limits.